Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
For the new study, Pratleys team tested it in a clinical trial of 102 people with body mass indexes classified as overweight or obese
But "most people" is not everyone
Increasing and sustaining weight loss
In a recent clinical trial, adults with obesity (without diabetes) lost an average of 20.2% of their body weight with tirzepatide as compared to 13.7% with semaglutide over 72 weeks
The GIP receptor activation in both tirzepatide and retatrutide appears to contribute substantially to insulin sensitization in fat tissue, which may explain why both outperform semaglutide on this metric
US$ 29.17
US$ 23.75
US$ 21.81
US$ 21.26
US$ 20.38
US$ 20.13
